Oh, So That's Why DOJ Isn't Going After Pro-Terrorism Agitators
The UN Endorses a Second Terrorist State for Iran
Jihad Joe
Israeli Ambassador Shreds the U.N. Charter in Powerful Speech Before Vote to Grant...
New Single Article of Impeachment Filed Against Biden
New Report Details How Dems Are Planning to Minimize Risk of Pro-Hamas Disruptions...
The Long Haul of Love
3,000 Fulton County Ballots Were Scanned Twice During the 2020 Election Recount
Joe Biden's Weapons 'Pause' Will Get More Israeli Soldiers, Civilians Killed
Left-Wing Mayor Hires Drag Queen to Spearhead 'Transgender Initiatives'
NewsNation Border Patrol Ride Along Sees Arrest of Illegal Immigrants in Illustration of...
One State Just Cut Off Funding for Planned Parenthood
Vulnerable Democratic Senators Refuse to Support Commonsense Pro-Life Bill
California Surf Competition Will Be Required to Allow Men to Compete Against Women
MSNBC Left Sputtering Over Poll's Findings on Who Independent Voters Worry Will 'Weaken...
OPINION

Will America Accept Bureaucratic Rationing of Healthcare?

The opinions expressed by columnists are their own and do not necessarily represent the views of Townhall.com.
Advertisement
Advertisement
Advertisement

The numbers are as startling as tragic. According to the Daily Mail, “Up to 20,000 people have died needlessly early after being denied cancer drugs on the NHS, it was revealed yesterday. The rationing body NICE has failed to keep a promise to make more life-extending drugs available.”

Advertisement

British cancer patients are routinely denied access to critical life-extending drugs because of their costs.

The Telegraph noted two year ago, that the British health care system’s decision to deny patients four kidney cancer drugs on the NHS was denounced by doctors as 'poor' and 'unsuitable'. They said it was a "tragedy" that Britain's leading role in cancer research was not being translated into treatment for all patients, who were often left struggling to pay for the drugs themselves. The decision has led patients to mortgage their house in order to obtain the drugs and treatment they need to survive.

The occurrences on the other side of the pond are notable not because they are rare, but because they are commonplace. There are no howls of protests from patients who are powerless and are forced to live under the dictates of bureaucrats who make life and death decisions based upon budget constraints and not what’s best for the patients. This is the fundamental basis of government-run health care.

And Americans are perhaps 60 days away from our cancer patients suffering a similar fate.

That’s because the Food and Drug Administration (FDA) has apparently opened the door to using cost as part of their evaluation process for drugs. The late-stage cancer drug Avastin has been proven effective in extending the life of cancer patients. Rather than testing the safety and efficacy of the drug, the FDA created a new standard that would allow patients who could afford the drug to use it, while those who cannot would be denied their use.

Advertisement

They are considering “de-labeling” the drug for breast cancer patients – essentially allowing Medicare and private insurance to deny coverage of the drug under their policies.

The FDA has moved a final decision about the fate of Avastin and breast cancer patients until after the elections. Not a great sign.

Will the American people accept the bureaucratic dictates that will deny them to a valuable treatment option or will they stand up and say rationing is not the American way?

Join the conversation as a VIP Member

Recommended

Trending on Townhall Videos